Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560413 | 0.87 | EPHX1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19172072 | 0.82 | NPC1 (0.42) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19171338 | 0.81 | NPC1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL10071176 | 0.80 | EPHX1 (0.60) | SMN1; SMN2KDM4CEPHX1ALDH1A1MMP1 | |
| SCHEMBL21761148 | 0.80 | KDM4C (0.41) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL23143102 | 0.80 | KDM4C (0.41) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL7816137 | 0.80 | KDM4C (0.67) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL20017302 | 0.79 | NPC1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL15341360 | 0.79 | NPC1 (0.46) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL618600 | 0.78 | EPHX1 (0.44) | NPC1RAB9ASMN1; SMN2KDM4CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-04 | — | — | US | disclosed |
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4488283-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-08 | — | — | EP | disclosed |
| CN-118715234-A | Process for producing peptide compound | 中外制药株式会社 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240067649-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11827632-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023195516-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | 中外製薬株式会社 | 2023-10-12 | — | — | WO | disclosed |
| US-20070093414-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| WO-2007003965-A1 | SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-4056527-A | HERBICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | CXCR3, CXCL10, CXCR1 | NPC1 1322/4885RAB9A 3513/4885MAPT 1320/4885 |
| US-11827632-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | NPC1 249/4885RAB9A 2621/4885MAPT 407/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | NPC1 4857/4885RAB9A 2482/4885MAPT 3719/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | NPC1 249/4885RAB9A 2621/4885MAPT 407/4885 |
| US-20070021611-A1 | Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CCR1, CCR5 | NPC1 2108/4885RAB9A 4073/4885MAPT 1640/4885 |
| US-20250276995-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | VIP, IAPP, QPCT | NPC1 3259/4885RAB9A 3692/4885MAPT 2138/4885 |
| US-20240067649-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NPC1 249/4885RAB9A 2621/4885MAPT 407/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | NPC1 398/4885RAB9A 2638/4885MAPT 4479/4885 |
| US-20070093414-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, PYGL | NPC1 167/4885RAB9A 1854/4885MAPT 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.